TP53 and head and neck squamous cell carcinoma: In our previous manuscript, we discussed the prevalence and implications of various gene alterations in HNSCC, and showed that not only was TP53 the most prevalent (present in 73.3% of patients’ tDNA and/or ctDNA samples), but it also predicted poor survival.6 Jiang et al.7 referenced these results and analyzed the prevalence and prognostic implications of TP53 alterations in a cohort of 1661 patients treated with immunotherapy (128 with HNSCC).